Google's AI Models Promise Drug Discovery Revolution

Google is diving into the world of drug discovery with its new "open" AI models, dubbed TxGemma.

Announced at a health-focused shindig in New York, these models are set to hit the scene later this month through Google’s Health AI Developer Foundations program.

TxGemma is designed to understand both everyday text and the nitty-gritty details of therapeutic entities like chemicals, molecules, and proteins. Google's chief health officer, Karen DeSalvo, highlighted the potential of these models to streamline the lengthy and costly drug development process. Researchers can use TxGemma to predict the safety and effectiveness of new therapies, potentially saving time and resources.

---

Want to hear more? Join Mal on the Property AI Report Podcast each week!

Access from your preferred podcast provider by clicking here

---

While Google has yet to spill the beans on whether these models will be open for commercial use or customization, the buzz is undeniable. AI has long been touted as the future of drug discovery, with companies like Google spin-out Isomorphic Labs leading the charge. Despite some setbacks, such as clinical trial hiccups from firms like Exscientia and BenevolentAI, the enthusiasm remains high.

Big pharma and investors are all in, with over 460 AI startups in the drug discovery race and a whopping $60 billion invested in the field. Isomorphic is even gearing up to test its AI-designed drugs this year, backed by partnerships with pharma heavyweights like Eli Lilly and Novartis.

While AI isn't a magic bullet just yet, the potential for a breakthrough is tantalising. Google's TxGemma might just be the catalyst the industry needs to accelerate drug discovery into the fast lane.

---

Want to hear more? Join Mal on the Property AI Report Podcast each week!

Access from your preferred podcast provider by clicking here

---

Made with TRUST_AI - see the Charter: https://www.modelprop.co.uk/trust-ai